CAS Number6903-79-3
Synonyms1-<Carbimidoyl-methyl-amino>-2-phosphonooxy-ethan; Creatinolo O-fosfato [Italian]; Creatinol phosphate; Aplodan; 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid; EINECS 230-011-8; 2-(1-Methylguanidino)ethyl dihydrogen phosphate; Creatinol O-phosphate; Kreatinol-phosphorsaeurester; 2-(N-Methylcarbamimidamido)ethyl dihydrogen phosphate; MFCD00868297; N-Methyl-N-(b-hydroxyethyl)guanidine O-Phosphate; creatinolfosfate; Creatinolfosfatum [INN-Latin]; Creatinolfosfato [INN-Spanish]
Molecular FormulaC4H12N3O4P
Molecular Weight197.13
Purity98%
Density1.7±0.1 g/cm3
Boiling Point384.1±52.0 °C at 760 mmHg
Melting Point244 °C(dec.)
Appearancesolid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 6903-79-3 |
| Catalog No. | 2A-9009923 |
| Chinese Name | 磷酸肌肉醇 |
| Synonyms | 1-<Carbimidoyl-methyl-amino>-2-phosphonooxy-ethan; Creatinolo O-fosfato [Italian]; Creatinol phosphate; Aplodan; 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid; EINECS 230-011-8; 2-(1-Methylguanidino)ethyl dihydrogen phosphate; Creatinol O-phosphate; Kreatinol-phosphorsaeurester; 2-(N-Methylcarbamimidamido)ethyl dihydrogen phosphate; MFCD00868297; N-Methyl-N-(b-hydroxyethyl)guanidine O-Phosphate; creatinolfosfate; Creatinolfosfatum [INN-Latin]; Creatinolfosfato [INN-Spanish] |
| Molecular Formula | C4H12N3O4P |
| Molecular Weight | 197.13 |
| Purity | 98 |
| Density | 1.7±0.1 g/cm3 |
| Boiling Point | 384.1±52.0 °C at 760 mmHg |
| Melting Point | 244 °C(dec.) |
| Appearance | solid |
| Storage Condition | -20°C |
| Application | Aprelotan is an anti-ischemic and antiarrhythmic drug. Aprodan has a protective effect on cell membranes. Aprelotan has potential in the study of ischemic heart disease or ischemic heart disease with |
| HTC | 2925290090 |
| PubChem ID | 329794872 |
| MDL Number | MFCD00868297 |
| SMILES | OP(OCCN(C)C(N)=N)(O)=O |
| InChI | 1S/C4H12N3O4P/c1-7(4(5)6)2-3-11-12(8,9)10/h2-3H2,1H3,(H3,5,6)(H2,8,9,10) |
| InChI Key | FOIPWTMKYXWFGC-UHFFFAOYSA-N |
| NACRES Code | NA.21 |
| UNSPSC | 12352200 |
| MSDS | msds/9923_1_6903_79_3.pdf |
| Bioactivity | Aplodan is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or ischemic heart disease with persistent ventricular premature beats (VPB) [1][2]. Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others References [1]. Botti G, et al. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelforschung. 1979;29(9a):1491-1494. [2]. Di Maio F, et al. Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial. Arzneimittelforschung. 1979;29(9a):1488-1490. Chemical & Physical Properties Density 1.7±0.1 g/cm3 Boiling Point 384.1±52.0 °C at 760 mmHg Melting Point 244 °C(dec.) Molecular Formula C4H12N3O4P Molecular Weight 197.130 Flash Point 186.1±30.7 °C Exact Mass 197.056549 PSA 129.68000 LogP -3.01 Vapour Pressure 0.0±1.9 mmHg at 25°C Index of Refraction 1.575 InChIKey FOIPWTMKYXWFGC-UHFFFAOYSA-N SMILES CN(CCOP(=O)(O)O)C(=N)N Storage condition -20°C |
| Use of | Aplodan is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or ischemic heart disease with persistent ventricular premature beats (VPB) [1][2]. Properties Name 2-[carbamimidoyl(methyl)amino]ethyl dihydrogen phosphate Synonym More Synonyms Aplodan Biological Activity Description Aplodan is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or ischemic heart disease with persistent ventricular premature beats (VPB) [1][2]. Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others References [1]. Botti G, et al. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelforschung. 1979;29(9a):1491-1494. [2]. Di Maio F, et al. Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial. Arzneimittelforschung. 1979;29(9a):1488-1490. Chemical & Physical Properties Molecular Formula C4H12N3O4P Exact Mass 197.056549 PSA 129.68000 LogP -3.01 Index of Refraction 1.575 InChIKey FOIPWTMKYXWFGC-UHFFFAOYSA-N SMILES CN(CCOP(=O)(O)O)C(=N)N |
| Tax Rebate | 9.0% |
| Supervision | none |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Nutritional Ingredients | ||
|---|---|---|
| Cinepazic Acid | 54063-23-9 | 2A-9009804 |
| Cinepazide | 23887-46-9 | 2A-9009805 |
| Cinepazide maleate | 26328-04-1 | 2A-9009806 |
| Cladribine | 4291-63-8 | 2A-9009825 |
| clary sage oil | 8016-63-5 | 2A-9009827 |
| Cyclocurcumin | 153127-42-5 | 2A-9009943 |
| Dialifos | 10311-84-9 | 2A-9010096 |
| Diclazuril | 101831-37-2 | 2A-9010120 |
| Dosergoside | 87178-42-5 | 2A-9010237 |
| Epalrestat | 82159-09-9 | 2A-9010338 |
| Browse all Nutritional Ingredients products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS